Proteomic analysis of serum proteins in triple transgenic alzheimer's disease mice: Implications for identifying biomarkers for use to screen potential candidate therapeutic drugs for early alzheimer's disease

Journal of Alzheimer's Disease

Volumn 40, Issue 3, 2014, Pages 575-586

  Sui, Xiaojing ^a,b,c   Ren, Xiaohu ^b   Huang, Peiwu ^b   Li, Shuiming ^d   Ma, Quan ^b   Ying, Ming ^d   Ni, Jiazuan ^a,d   Liu, Jianjun ^b  

^a CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY   (China)

^b SHENZHEN CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^d SHENZHEN UNIVERSITY   (China)

Author keywords

Alzheimer's disease; coenzyme Q10; serum; two dimensional fluorescence difference gel electrophoresis

Indexed keywords

ALPHA 2 MACROGLOBULIN; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; BRAIN PROTEIN; CLUSTERIN; PLASMA PROTEIN; UBIDECARENONE; AMYLOID PRECURSOR PROTEIN; ANTIOXIDANT; PRESENILIN 1; PSEN1 PROTEIN, HUMAN; TAU PROTEIN; UBIQUINONE;

3XTG MOUSE; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEOMICS; TANDEM MASS SPECTROMETRY; THERAPY EFFECT; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MASS SPECTROMETRY; METABOLISM; MUTATION; PROCEDURES; PROTEIN DATABASE; STATISTICS AND NUMERICAL DATA; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIOXIDANTS; BLOOD PROTEINS; DATABASES, PROTEIN; DISEASE MODELS, ANIMAL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; HUMANS; MICE; MICE, TRANSGENIC; MUTATION; PRESENILIN-1; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TAU PROTEINS; UBIQUINONE;

EID: 84901917788     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-131823     Document Type: Article

References (44)

1. Alzheimer's Disease International (2009) World Alzheimer Report 2009. Alzheimer's Disease International, London.
2. Wimo A, PrinceM(2010)World Alzheimer Report 2010: The Global Economic Impact of Dementia. Alzheimer's Disease International, London.
3. Cummings JL (2011) Biomarkers in Alzheimer's disease drug development. Alzheimers Dementia 7, e13-e44.
4. Blennow K (2005) CSF biomarkers for Alzheimer's disease: Use in early diagnosis and evaluation of drug treatment. Expert Rev Mol Diagnostics 5, 661-672. (Pubitemid 41337462)
5. Mulder C,VerweyNA, van der FlierWM,Bouwman FH,Kok A, van Elk EJ, Scheltens P, BlankensteinMA(2010) Amyloidbeta (1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem 56, 248-253.
6. Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, Byers HL, Hooper C, Rijsdijk F, Tabrizi SJ, Banner S, Shaw CE, Foy C, Poppe M, Archer N, Hamilton G, Powell J, Brown RG, Sham P, Ward M, Lovestone S (2006) Proteome-based plasma biomarkers for Alzheimer's disease. Brain 129, 3042- 3050. (Pubitemid 44684524)
7. Lehninger AL (1971) The molecular organization of mitochondrial membranes. Adv Cytopharmacol 1, 199-208.
8. Beyer RE (1992) An analysis of the role of coenzyme Q in free radical generation and as an antioxidant. Biochem Cell Biol 70, 390-403.
9. Beal MF (2004) Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. J Bioenerg Biomembr 36, 381-386. (Pubitemid 39619845)
10. Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M, Parkinson Study G (2002) Effects of coenzyme Q10 in early Parkinson disease: Evidence of slowing of the functional decline. Arch Neurol 59, 1541-1550.
11. Young AJ, Johnson S, Steffens DC, Doraiswamy PM (2007) Coenzyme Q10: A review of its promise as a neuroprotectant. CNS Spectr 12, 62-68. (Pubitemid 46155305)
12. Yang X, Dai G, Li G, Yang ES (2010) Coenzyme Q10 reduces [beta]-amyloid plaque in an APP/PS1 transgenic mouse model of Alzheimer's disease. J Mol Neurosci 41, 110- 113.
13. Elipenahli C, Stack C, Jainuddin S, Gerges M, Yang L, Starkov A, Beal MF, Dumont M (2012) Behavioral improvement after chronic administration of coenzyme Q10 in P301S transgenic mice. J Alzheimers Dis 28, 173-182.
14. Dumont M, Kipiani K, Yu F, Wille E, Katz M, Calingasan NY, Gouras GK, Lin MT, Beal MF (2011) Coenzyme Q10 decreases amyloid pathology and improves behavior in a transgenic mouse model of Alzheimer's disease. J Alzheimers Dis 27, 211-223.
15. Koh S-H, Choi H, Park H-H, Lee K-Y, Lee YJ, Kim SH (2010) Neuroprotective effects of Coenzyme Q10 against beta-amyloid-induced neural stem cell death. Alzheimers Dement 6, S209.
16. Beckett P (2012) The basics of 2D DIGE. Methods Mol Biol 854, 9-19.
17. Robinson RAS, Joshi G, Huang Q, Sultana R, Baker AS, Cai J, Pierce W, St. Clair DK, Markesbery WR, Butterfield DA (2011) Proteomic analysis of brain proteins in APP/PS-1 human double mutant knock-in mice with increasing amyloid -peptide deposition: Insights into the effects of in vivo treatment with N-acetylcysteine as a potential therapeutic intervention in mild cognitive impairment and Alzheimer's disease. Proteomics 11, 4243-4256.
18. Sultana R, Boyd-Kimball D, Cai J, Pierce WM, Klein JB, Merchant M, Butterfield DA (2007) Proteomics analysis of the Alzheimer's disease hippocampal proteome. J Alzheimers Dis 11, 153-164. (Pubitemid 47010980)
19. Cummings JL (2004) Alzheimer's disease. N Engl J Med 351, 56-67.
20. Craig-Schapiro R, Fagan AM, Holtzman DM (2009) Biomarkers of Alzheimer's disease. Neurobiol Dis 35, 128- 140.
21. Rapoport SI, Nelson PT (2011) Biomarkers and evolution in Alzheimer disease. Prog Neurobiol 95, 510-513.
22. Mayeux R, Schupf N (2011) Blood-based biomarkers for Alzheimer's disease: Plasma A beta 40 and A beta 42, and genetic variants. Neurobiol Aging 32, S10-S19.
23. O'Bryant SE, Xiao G, Barber R, Huebinger R, Wilhelmsen K, Edwards M, Graff-Radford N, Doody R, Diaz-Arrastia R; Texas Alzheimer's Research&Care Consortium; Alzheimer's Disease Neuroimaging Initiative (2011) A blood-based screening tool for Alzheimer's disease that spans serum and plasma: Findings from TARC and ADNI. Plos One 6, e28092.
24. Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6, 131-144.
25. Blennow K, Hampel H (2003) CSF markers for incipient Alzheimer's disease. Lancet Neurol 2, 605-613. (Pubitemid 37162569)
26. Nagele E, Han M, DeMarshall C, Belinka B, Nagele R (2011) Diagnosis of Alzheimer's disease based on disease-specific autoantibody profiles in human sera. Plos One 6, e23112.
27. Choi H, Park H-H, Koh S-H, Choi N-Y, Yu H-J, Park J, Lee YJ, Lee K-Y (2012) Coenzyme Q10 protects against amyloid beta-induced neuronal cell death by inhibiting oxidative stress and activating the P13K pathway. Neurotoxicology 33, 85-90.
28. Velliquette RA, O'Connor T, Vassar R (2005) Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: Possible early events in Alzheimer's disease pathogenesis. J Neurosci 25, 10874-10883. (Pubitemid 41692617)
29. Ghiso J, Matsubara E, Koudinov A, Choi-Miura NH, Tomita M,Wisniewski T, FrangioneB(1993) The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem J 293(Pt 1), 27-30. (Pubitemid 23223142)
30. Oda T, Wals P, Osterburg HH, Johnson SA, Pasinetti GM, Morgan TE, Rozovsky I, Stine WB, SnyderSW, Holzman TF, et al. (1995) Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1-42) and forms slowly sedimenting A beta complexes that cause oxidative stress. Exp Neurol 136, 22-31.
31. Zlokovic BV (1996) Cerebrovascular transport of Alzheimer's amyloid beta and apolipoproteins J and E: Possible anti-amyloidogenic role of the blood-brain barrier. Life Sci 59, 1483-1497. (Pubitemid 26358266)
32. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K,Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schurmann B, van den Bussche H, Heuser I, Kornhuber J,Wiltfang J, Dichgans M, Frolich L, Hampel H, Hull M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van BroeckhovenC,Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel KH, Klopp N,Wichmann HE, Carrasquillo MM, Pankratz VS,Younkin SG, Holmans PA, O'DonovanM, Owen MJ,Williams J (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 41, 1088-1093.
33. Ijsselstijn L, Dekker LJM, Koudstaal PJ, Hofman A, Sillevis Smitt PAE, Breteler MMB, Luider TM (2011) Serum clusterin levels are not increased in presymptomatic Alzheimer's disease. J Proteome Res 10, 2006-2010.
34. Wyatt AR, Constantinescu P, Ecroyd H, Dobson CM,Wilson MR, Kumita JR, Yerbury JJ (2013) Protease-activated alpha- 2-macroglobulin can inhibit amyloid formation via two distinct mechanisms. FEBS Lett 587, 398-403.
35. Blacker D,Wilcox MA, Laird NM, Rodes L, Horvath SM, Go RC, Perry R, Watson B, Jr., Bassett SS, McInnis MG, Albert MS, Hyman BT, Tanzi RE (1998) Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet 19, 357-360. (Pubitemid 28357907)
36. Ribeiro CA, Santana I, Oliveira C, Baldeiras I, Moreira J, Saraiva MJ, Cardoso I (2012) Transthyretin decrease in plasma of MCI and AD patients: Investigation of mechanisms for disease modulation. Curr Alzheimer Res 9, 881-889.
37. Schwarzman AL, Gregori L, Vitek MP, Lyubski S, Strittmatter WJ, Enghilde JJ, Bhasin R, Silverman J, Weisgraber KH, Coyle PK (1994) Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc Natl Acad SciUSA 91, 8368-8372. (Pubitemid 24273665)
38. Tsuzuki K, Fukatsu R, Yamaguchi H, Tateno M, Imai K, Fujii N, Yamauchi T (2000) Transthyretin binds amyloid beta peptides, Abeta1-42 and Abeta1-40 to form complex in the autopsied human kidney - possible role of transthyretin for abeta sequestration. Neurosci Lett 281, 171-174. (Pubitemid 30125892)
39. Cui Y, Huang M, He Y, Zhang S, Luo Y (2011) Genetic ablation of apolipoprotein A-IV accelerates Alzheimer's disease pathogenesis in a mouse model. Am J Pathol 178, 1298-1308.
40. Hui X, Zhu W, Wang Y, Lam KS, Zhang J, Wu D, Kraegen EW, Li Y, Xu A (2009) Major urinary protein-1 increases energy expenditure and improves glucose intolerance through enhancing mitochondrial function in skeletal muscle of diabetic mice. J Biol Chem 284, 14050-14057.
41. Davidsson P, Sj?ogren M (2006) Proteome studies of CSF in AD patients. Mech Ageing Dev 127, 133-137. (Pubitemid 43165612)
42. Tolosano E, Hirsch E, Patrucco E, Camaschella C, Navone R, Silengo L, Altruda F (1999) Defective recovery and severe renal damage after acute hemolysis in hemopexin-deficient mice. Blood 94, 3906-3914.
43. Cocciolo A, Di Domenico F, Coccia R, Fiorini A, Cai J, Pierce WM,Mecocci P, ButterfieldDA, PerluigiM(2012) Decreased expression and increased oxidation of plasma haptoglobin in Alzheimer disease: Insights from redox proteomics. Free Radic Biol Med 53, 1868-1876.
44. Hatoh T, Maeda T, Takeuchi K, Ogikubo O, Uchiyama S, Otsuka T, Ohkubo I, Ogita H (2012) Domain 5 of high molecular weight kininogen inhibits collagen-mediated cancer cell adhesion and invasion in association with alpha-actinin-4. Biochem Biophys Res Commun 427, 497-502.